ABACAVIR,LAMIVUDINE
Background and Date of Approval
Abacavir and Lamivudine are antiretroviral medications containing the active constituents Abacavir and Lamivudine. Both medications belong to a class of drugs called nucleoside reverse transcriptase inhibitors (NRTIs) and are often used in combination with other antiretroviral drugs as part of highly active antiretroviral therapy (HAART) or combination antiretroviral therapy (cART). They are used to treat HIV-1 infection. HIV-1 is a virus known as the Human immunodeficiency virus, which targets and destroys immune system cells, ultimately weakening the body's defence against infections. If left untreated, it can result in death. While these medications do not offer a complete cure, they effectively reduce the virus levels in your body and increase the count of CD4 cells in your bloodstream. These cells play a crucial role in assisting your body's fight against infections. The initial FDA approval date for abacavir was December 17, 1998; lamivudine was November 17, 1995.
Uses
Abacavir and Lamivudine are used in the treatment of HIV-1 infection.
How is it administered?
To use Abacavir and Lamivudine, follow your healthcare provider's prescribed dosage and instructions. Take the medications as directed, usually orally, with or without food. Do not skip doses or stop taking them without consulting your healthcare provider. Consult your healthcare provider or pharmacist for guidance if you have any questions or concerns.
Side Effects
Abacavir and lamivudine may produce common side effects encompassing headache, nausea, diarrhea, fatigue, rash, and abdominal pain. Less frequently, individuals may experience severe hypersensitivity reactions, which can be life-threatening and require immediate medical attention. Other potential side effects include liver abnormalities, lactic acidosis (accumulation of lactic acid in the blood), and changes in body fat distribution.
Warnings
When using abacavir and lamivudine, it is important to be aware of potential warnings and risks. These include the possibility of severe hypersensitivity reactions to abacavir, the risk of lactic acidosis with lamivudine, the potential for immune reconstitution inflammatory syndrome, the need for monitoring in individuals with liver or kidney impairment, the rare occurrence of pancreatitis with lamivudine, changes in body fat distribution, interactions with other medications, and considerations for pregnancy and breastfeeding.
Precautions
Discussing these warnings with your healthcare provider to ensure these medications' safe and appropriate use is essential. When using abacavir and lamivudine, it is important to adhere to the prescribed dosage and follow the instructions provided by your healthcare provider. Before starting treatment, inform your healthcare provider about any medical conditions, allergies, or medications you are taking. Regular monitoring of liver function and kidney function is advised. If you experience symptoms of a hypersensitivity reaction, such as fever, rash, or respiratory symptoms, discontinue the medication and seek immediate medical attention. Avoid alcohol and be cautious when driving or operating machinery, as these medications may cause dizziness or drowsiness. Consult your healthcare provider before changing your treatment regimen or starting new medications.
Word of Advice
Follow the prescribed dosage and instructions for abacavir and lamivudine. Genetic screening for hypersensitivity reactions is essential before initiating therapy; seek immediate medical attention if symptoms develop. Monitor for lactic acidosis, assess liver function regularly, and modify dosages in patients with renal impairment. Be aware of immune reconstitution inflammatory syndrome, pancreatitis symptoms, and alterations in body fat distribution. Account for potential drug interactions and discuss use during pregnancy and breastfeeding with your healthcare provider. Use in elderly patients and children requires individualised assessment. Strict adherence and open communication with your healthcare provider ensure safe use of this medication.
References
KD Tripathi, Essentials of Medical Pharmacology, Antiviral drugs, 7th edition, 2013, 807-808. Goodman & Gilmanâs, The Pharmacological Basis of Therapeutics, Antiretroviral agents and treatment of HIV infection, 12th edition, 2011, 1635-1636. Lupin Healthcare (UK) Limited, Electronic medicines compendium (EMC), [ Revised on April 2023] [ Accessed on 27th May 2023], https://www.medicines.org.uk/emc/landing/status=1 ViiV Healthcare, US Food, and Drug Administration, [ Revised on May 2019] [ Accessed on 27th May June 2023], https://www.accessdata.fda.gov/drugsatfda_docs/pepfar/090519PI.pdf
Frequently Asked Questions
What is immune reconstitution inflammatory syndrome (IRIS), and how is it managed?
Immune reconstitution inflammatory syndrome can occur when starting antiretroviral therapy, including abacavir and lamivudine, in individuals with advanced HIV infection. The sudden onset or worsening of inflammatory conditions characterizes it. The management of IRIS involves treating underlying infections or inflammatory conditions and providing supportive care.
Are there any specific tests or screenings required before starting abacavir and lamivudine?
Before starting abacavir and lamivudine, it is recommended to undergo genetic screening (HLA-B*5701) to identify individuals at higher risk of a hypersensitivity reaction. This screening helps in determining the suitability of abacavir use.
Can abacavir and lamivudine be used in patients with pre-existing liver or kidney disease?
Caution should be exercised when using abacavir and lamivudine in individuals with pre-existing liver or kidney disease. Close monitoring of liver and kidney function may be necessary, and dose adjustments may be required based on the severity of the impairment.
Can abacavir and lamivudine be used in patients with hepatitis B or hepatitis C?
Abacavir and lamivudine can be used in individuals with HIV and hepatitis B or C coinfections. These medications have activity against the hepatitis B virus (HBV) and can help manage both infections simultaneously. However, it's important to consult with a healthcare provider who can assess the specific circumstances and determine the most appropriate treatment approach.
Can abacavir and lamivudine cause long-term complications?
While abacavir and lamivudine are generally well-tolerated, long-term medication use can carry potential risks. Regular monitoring and follow-up with a healthcare provider are important to assess treatment response, monitor for side effects, and manage potential long-term complications.
Can I restart Abacavir and Lamivudine if I previously had a hypersensitivity reaction?
Once a hypersensitivity reaction to Abacavir and Lamivudine has occurred, the medication should not be restarted, as it can lead to a potentially life-threatening reaction. It is crucial to inform all healthcare providers about your hypersensitivity reaction history to prevent accidental re-initiation of abacavir in the future.